Impact of prior systemic corticosteroid use in patients admitted with community-acquired pneumonia

Therapeutic Advances in Respiratory Disease

Volumn 6, Issue 6, 2012, Pages 323-330

  Malave, Adriel ^a   Laserna, Elena ^a,b   Sibila, Oriol ^a,c   Mortensen, Eric M ^d   Anzueto, Antonio ^e   Restrepo, Marcos I ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Hospital Comarcal de Mollet   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

corticosteroids; drug resistance; microbial; mortality; pneumonia; severity of illness index

Indexed keywords

CORTICOSTEROID; CORTISONE; DEXAMETHASONE; FLUDROCORTISONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADULT; AGED; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 84870192191     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465812458985     Document Type: Article

References (29)

1. Agusti C. Rano A. Filella X. Gonzalez J. Moreno A. Xaubet A. (2003) Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment. Etiology, prognosis factors and associated inflammatory response. Chest 123: 488–498.
2. Bone R. Sibbald W. Sprung C. (1992) The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101: 1481–1483.
3. Conesa D. Rello J. Valles J. Mariscal D. Ferreres J. (1995) Invasive aspergillosis: a life-threatening complication of short-term steroid treatment. Ann Pharmacother 29: 1235–1237.
4. Confalonieri R. Rubino G. Potena A. Piattella M. Parigi P. Puccio G. (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171: 242–248.
5. Falguera M. Carratala J. Ruiz-Gonzalez A. Garcia-Vidal C. Gazquez I. Dorca J. (2009) Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology 14: 105–111.
6. Fine M. Auble T. Yealey D. Hanusa B. Weissfeld L. Singer D. (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Eng J Med 336: 243–250.
7. Garcia-Vidal C. Calbo E. Pascual V. Ferrer C. Quintana S. Garau J. (2007) Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 30: 951–956.
8. Jemal A. Ward E. Hao Y. Thun M. (2005) Trends in the leading causes of death in the United States, 1970–2002. JAMA 294: 1255–1259.
9. Lim W. van de Eerden M. Laing R. Boersma W. Karalus N. Town G. (2003) Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58: 377–382.
10. Mandell L. Wunderink R. Anzueto A. Bartlett J. Campbell G. Dean N. (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines for the management of community acquired pneumonia in adults. Clin Infect Dis 44: S27's72.
11. Martinez R. Menendez R. Reyes S. Santos M. Valles J. Modesto M. (2007) Pulmonary nocardiosis: risk factors and outcomes. Respirology 12: 394–400.
12. Maskell N. Waine D. Lindley A. Pepperell J. Wakefield A. Miller R. (2003) Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 58: 594–597.
13. Meijvis S. Hardeman H. Remmelts H. Heijligenberg R. Rijkers G. van Velzen-Blad H. (2011) Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomized, double-blind, placebo-controlled trial. Lancet 377: 2023–2030.
14. Menendez R. Cavalcanti M. Reyes S. Mensa J. Martinez R. Marcos M. (2008) Markers of treatment failure in hospitalized community-acquired pneumonia. Thorax 63: 447–452.
15. Menendez R. Martinez R. Reyes S. Mensa J. Filella X. Marcos M. (2009) Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 64: 587–591.
16. Monton C. Ewig S. Torres A. El-Ebiary M. Filella X. Rano A. (1999) Role of glucocorticoids on inflammatory response on inflammatory response in nonimmunosuppressed patients with pneumonia. A pilot study. Eur Respir J 14: 218–220.
17. Murphy T. Brauer A. Eschberger K. Lobbins P. Grove L. Cai X. (2008) Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 853–860.
18. Niederman M. Mandell L. Anzueto A. Bass J. Broughton W. Campbell G. (2001) American Thoracic Society guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 163: 1730–1754.
19. Rano A. Agusti C. Sibila O. Torres A. (2006) Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids. Curr Opin Infect Dis 19: 179–184.
20. Rhen T. Cidlowski J. (2005) Antiinflammatory action of glucocorticoids ’ new mechanisms for old drugs. N Engl J Med 20: 1711–1723.
21. Sanders K. Marras T. Chan C. (2006) Pneumonia severity index in the immunocompromised. Can Respir J 13: 89–93.
22. Schacke H. Docke W. Asadullah K. (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23–43.
23. Sibila O. Agusti C. Torres A. (2008a) Corticoesteroids in severe pneumonia. Eur Respir J 32: 259–264.
24. Sibila O. Luna C. Agusti C. Baquero S. Gando S. Patron J. (2008b) Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J 32: 1037–1046.
25. Snijders D. Daniels J. De Graaff C. van der Werf T. Boersma W. (2010) Efficacy of corticosteroids in community-acquired pneumonia. A randomised double-blinded clinical trial. Am J Respir Crit Care Med 181: 975–982.
26. Sousa D. Justo I. Dominguez A. Manzur A. Izquierdo C. Ruiz L. (2012) Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome. Clin Microbiol Infect 10 January (epub ahead of print) doi: 10.1111/j.1469-0691.2012.03765.x.
27. Stuck A. Minder C. Frey F. (1989) Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 69: 954–963
28. Wagner H. Bennet I. Lasagna L. Cluff L. Rosenthal M. Mirick G. (1956) The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 98: 197–215.
29. Wiest P. Flanigan T. Salalta R. Shlaes D. Katzman M. Lederman M. (1989) Serious complications of corticosteroid therapy for COPD. Chest 95: 1180–1184.